Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by FRASER, S. M.
Right arrow Articles by BIRD, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FRASER, S. M.
Right arrow Articles by BIRD, H. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

SULPHASALAZINE IN THE MANAGEMENT OF PSORIATIC ARTHRITIS

S. M. FRASER*, R. HOPKINS{dagger}, J. A. HUNTER{ddagger}, V. NEUMANN{dagger}, H. A. CAPELL* and H. A. BIRD{dagger}

*Centre for Rheumatic Diseases, University Department of Medicine, Glasgow Royal Infirmary
{dagger}Clinical Pharmacology Unit (Rheumatism Research), Royal Bath Hospital Harrogate
{ddagger}Cartnavel General Hospital Glasgow

There are few ‘second-line’ drugs available for the treatment of PSA and their use is often limited by toxicity. Thirty-nine patients with active PSA recruited from two rheumatology units were randomly allocated to either enteric-coated sulphasalazine (SASP) or placebo and followed for 24 wk. Six patients in the SASP group and 11 on placebo discontinued therapy before 24 wk.

Evaluation of effect of treatment revealed significant improvements in articular index in both groups at 12 wk. By 24 wk the articular index in placebo group was still showing benefit. In addition to articular index the SASP group improved significantly in terms of visual analogue scale, duration of morning stiffness and ESR.

SASP is effective in PSA but the partial clinical response to placebo indicates the importance of placebo-controlled studies in this variable disease.

KEY WORDS: Skin, Arthritis, Treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of Rheumatology SupplementHome page
N. J. McHUGH
Traditional Schemes for Treatment of Psoriatic Arthritis
J Rheumatol Suppl, August 1, 2009; 83(0): 49 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
V Ravindran, D L Scott, and E H Choy
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
Ann Rheum Dis, June 1, 2008; 67(6): 855 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Nash and D O Clegg
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii74 - ii77.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Pipitone, G. H. Kingsley, A. Manzo, D. L. Scott, and C. Pitzalis
Current concepts and new developments in the treatment of psoriatic arthritis
Rheumatology, October 1, 2003; 42(10): 1138 - 1148.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.